Weak US outlook, pricing pressures weigh on Sun Pharma's revenue growth

Sun Pharmaceutical’s June quarter results were weighed down by weak sales in the US market, especially in the high-margin specialty segment. Its American sales slid 24.6 per cent on a sequential basis, as Sun’s specialty portfolio, as well as its subsidiary Taro Pharma’s sales, dipped 33-38 per cent. Taro Pharma, which accounted for 42 per cent of Sun’s US sales, reported its worst quarterly performance in nine years.  The derma (skin) product segment, which accounts for around two-thirds of Taro’s sales, was the worst-affected due to pricing pressures......

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.